TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10206440

Group type: EXPERIMENTAL
Intervention: Hypoosmolality induced by intravenous administration of desmopressin, liberal ingestion of water, and infusion of hypotonic (0.45%) saline solution
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hypoosmolality during hyperinsulinemia and euglycemic clamping
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hypoosmolality
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (isoosmolar conditions)
Number of subjects: 7
Study: 7615114

Group type: EXPERIMENTAL
Intervention: Hysteroscopic GIFT
Number of subjects: 133

Group type: COMPARATOR
Intervention: Laparoscopic GIFT
Number of subjects: 133
Study: 2514824

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion starting at 2 mU/min up to 16 mU/min during the second stage of labour
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo infusion during the second stage of labour
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 226
Study: 327432

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Progressive relaxation treatment
Number of subjects: 24
Study: 31931444

Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2) plus cisplatin (80 mg/m2) (arm A)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m2) plus carboplatin (AUC 6) (arm B)
Number of subjects: 111
Study: 31124931

Group type: EXPERIMENTAL
Intervention: Grape seed proanthocyanidin extract (GSPE) 150 mg/d
Number of subjects: 124

Group type: COMPARATOR
Intervention: Calcium dobesilate (CD) 750 mg/d
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 29020962

Group type: EXPERIMENTAL
Intervention: Manipulation under anesthesia (MUA) followed by an intensive physiotherapy treatment protocol.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Physiotherapy (PT) alone, with advice and education based on guidelines.
Number of subjects: 82
Study: 25618535

Group type: EXPERIMENTAL
Intervention: General anaesthesia and bilateral nerve stimulator-guided pudendal nerve block (15 mL of Ropivacaïne 5 mg.mL(‐1)+0,5 μg.kg(‐1) of Clonidine)
Number of subjects: 83

Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 83
Study: 23714325

Group type: EXPERIMENTAL
Intervention: Micronutrient fortified yoghurt (FY)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Non-fortified yoghurt (NFY)
Number of subjects: 1010
Study: 21852579

Group type: EXPERIMENTAL
Intervention: Minocycline-EDTA lock solution
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional unfractionated heparin
Number of subjects: 204
Study: 19151302

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (200 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 2% lidocaine (100 mg + 400 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (300 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine with 2% lidocaine (150 mg + 400 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: bupivacaine-lidocaine mixture
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: ropivacaine-lidocaine mixture
Number of subjects: 82

Group type: COMPARATOR
Intervention: bupivacaine alone
Number of subjects: 82

Group type: COMPARATOR
Intervention: long-acting local anesthetic alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: mixture of long-acting local anesthetic with lidocaine
Number of subjects: 82
Study: 17014429

Group type: EXPERIMENTAL
Intervention: Probiotic (3 x 10(9)Lactobacillus acidophilus LAVRI‐A1; Probiomics)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo (maltodextrin alone)
Number of subjects: 178
Study: 12713754

Group type: EXPERIMENTAL
Intervention: Inclusive (in-group) prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exclusive (out-group) prime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral prime
Number of subjects: 0
Study: 10960406

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 36

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 36
Study: 9004851

Group type: EXPERIMENTAL
Intervention: Educational program for the prevention of allergic diseases (A2 group, n = 15)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Control group (A1 group, n = 20)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Validation of laboratory tests (group B, n = 66)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Validation of immunoclinical diagnoses (group C, n = 364)
Number of subjects: 482
Study: 1456564

Group type: EXPERIMENTAL
Intervention: 0.3 ppm NO2 exposure for 4 hours with exercise sessions
Number of subjects: 26

Group type: COMPARATOR
Intervention: Clean air exposure for 4 hours with exercise sessions
Number of subjects: 26

Group type: COMPARATOR
Intervention: Field self-measurements during clean air weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Field self-measurements during NO2 exposure weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Field data
Number of subjects: 26
Study: 6422802

Group type: EXPERIMENTAL
Intervention: Continuous epidural anaesthesia for 24 hours
Number of subjects: 18

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 18
Study: 30365955

Group type: EXPERIMENTAL
Intervention: Surgical intervention (133 patients, 65%)
Number of subjects: 204

Group type: COMPARATOR
Intervention: No surgical intervention (37 patients, 18%)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Sublobar resections (56 patients, 42%)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Lobectomies (60 patients, 45%)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Pneumonectomies (17 patients, 13%)
Number of subjects: 204
Study: 29802800

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 100
Study: 27343711

Group type: EXPERIMENTAL
Intervention: TXA Soaked Gelfoam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gelfoam
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 25440809

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg on admission followed by 20 mg/d; statin group, n = 252)
Number of subjects: 504

Group type: COMPARATOR
Intervention: No statin treatment (control group, n = 252)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Statin-treated patients
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 504
Study: 23157904

Group type: EXPERIMENTAL
Intervention: One-stage posterior correction and instrumentation without neurosurgery for syringomyelia.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Neurosurgery (suboccipital decompression and syrinx shunting) followed by scoliosis correction.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (study and control).
Number of subjects: 19
Study: 20168272

Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse diode laser
Number of subjects: 50

Group type: COMPARATOR
Intervention: Modified Early Treatment Diabetic Retinopathy Study laser photocoagulation
Number of subjects: 50
Study: 17413477

Group type: EXPERIMENTAL
Intervention: 5‐item Core Outcome Measure for whiplash (Core Whiplash Outcome Measure [CWOM])
Number of subjects: 481
Study: 15623999

Group type: EXPERIMENTAL
Intervention: Xeno III
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AdheSE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: optiBond solo Plus Self Etch
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prime & Bond NRC Nt
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control bonding system (Prime & Bond NT) with phosphoric acid pre-etch
Number of subjects: 100
Study: 12406532

Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 2400 mg/day, titrated to 900 mg/day over 3 days, then increased as needed)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 305
Study: 10576366

Group type: EXPERIMENTAL
Intervention: 3000 mg bismuth subnitrate (BSN)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 480 mg colloidal bismuth subcitrate (CBS)
Number of subjects: 20
Study: 8921139

Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone (MP)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Combination chemotherapy (VCMP/VBAP)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Elderly patients (70 years or more)
Number of subjects: 178
Study: 1888630

Group type: EXPERIMENTAL
Intervention: C 50/HCTZ 25 once daily
Number of subjects: 199

Group type: COMPARATOR
Intervention: C 25/HCTZ 12.5 twice daily
Number of subjects: 199
Study: 6638418

Group type: EXPERIMENTAL
Intervention: Endobronchial double lumen tube for one-lung ventilation with intravenous anaesthesia and muscular relaxation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional endotracheal intubation
Number of subjects: 6
Study: 30136045

Group type: EXPERIMENTAL
Intervention: TDF plus PEG‐IFN for 48 weeks (group A)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: TDF plus PEG‐IFN for 16 weeks followed by TDF for 32 weeks (group B)
Number of subjects: 740

Group type: COMPARATOR
Intervention: TDF for 120 weeks (group C)
Number of subjects: 740

Group type: COMPARATOR
Intervention: PEG‐IFN for 48 weeks (group D)
Number of subjects: 740
Study: 28660669

Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CBWT
Number of subjects: 103

Group type: COMPARATOR
Intervention: WL
Number of subjects: 103
Study: 26406150

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg daily)
Number of subjects: 658

Group type: COMPARATOR
Intervention: Everolimus (10 mg daily)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 658

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 658
Study: 23873901

Group type: EXPERIMENTAL
Intervention: Combination treatment with intravitreal ranibizumab and topical ketorolac (group 1)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ranibizumab alone (group 2)
Number of subjects: 56
Study: 19787290

Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: standard therapy (control)
Number of subjects: 36
Study: 19033682

Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate (VS, 50 mg p.o. twice daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16481737

Group type: EXPERIMENTAL
Intervention: 131I-labeled Metuximab (18.5 MBq/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 131I-labeled Metuximab (27.75 MBq/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 131I-labeled Metuximab (37 MBq/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 131I-labeled Metuximab
Number of subjects: 24
Study: 15370932

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) + Relapse Prevention therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Naltrexone (placebo) + Drug Counseling
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups (including both NTX and placebo)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Active medication group (NTX)
Number of subjects: 80
Study: 11092518

Group type: EXPERIMENTAL
Intervention: Soy breakfast cereal (providing 36 g/d soy protein and 168 mg/d isoflavones)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control breakfast cereal
Number of subjects: 25
Study: 9327316

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study: 8104730

Group type: EXPERIMENTAL
Intervention: Preoperative platelet-rich plasma (PRP) 10 ml.kg-1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group without plateletpheresis
Number of subjects: 40
Study: 3082694

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray plus terfenadine tablets (50 mcg flunisolide to each nostril twice daily and 60 mg terfenadine twice daily)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Terfenadine alone (60 mg terfenadine twice daily)
Number of subjects: 99
Study: 3272745

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25% epidural, 6 to 12 ml/hour)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg intramuscularly, no more frequently than every 4 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 24
Study: 29374796

Group type: EXPERIMENTAL
Intervention: Baseline subfoveal choroidal thickness (SCT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Baseline SCT ≤124 μm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve (ROC) analysis
Number of subjects: 60
Study: 27530775

Group type: EXPERIMENTAL
Intervention: Self-management web portal for COPD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher levels of personal assistance integrated in existing care program
Number of subjects: 0
Study: 26060503

Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 50
Study: 23699530

Group type: EXPERIMENTAL
Intervention: Peripheral sounds that preceded task-relevant visual targets (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral sounds presented during purely auditory tasks (Experiments 2-4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sudden, intrusive sounds
Number of subjects: 0
Study: 20506391

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg, 2 subcutaneous injections at 7-day intervals)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 18402744

Group type: EXPERIMENTAL
Intervention: KS pistol grip (26173 KC)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ethicon driver (E 705R)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: KS finger grip (26167 SK)
Number of subjects: 6

Group type: COMPARATOR
Intervention: KS palm grip (26173 ML)
Number of subjects: 6
Study: 16368471

Group type: EXPERIMENTAL
Intervention: S21400 150 microg per day
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: S21400 300 microg per day
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 15042530

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 11393212

Group type: EXPERIMENTAL
Intervention: Classical bar soap
Number of subjects: 25

Group type: COMPARATOR
Intervention: Syndet cleansing bar
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Soap chamber test with classical bar soap
Number of subjects: 25

Group type: COMPARATOR
Intervention: Soap chamber test with syndet bar
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bioengineering measurements with classical bar soap
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bioengineering measurements with syndet bar
Number of subjects: 25
Study: 9059137

Group type: EXPERIMENTAL
Intervention: Prednisolone at 2.00 am (5 or 7.5 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Prednisolone at 7.30 am (5 or 7.5 mg daily)
Number of subjects: 26
Study: 8365303

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Inverse Ratio Ventilation (PC-IRV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 10
Study: 2874527

Group type: EXPERIMENTAL
Intervention: Cysteamine (somatostatin-depleting agent) at maximum tolerated dosage for 2 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cysteamine (somatostatin-depleting agent)
Number of subjects: 5
Study: 29982534

Group type: EXPERIMENTAL
Intervention: Fructans (6 g/d)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Maltodextrin (control)
Number of subjects: 270
Study: 24876451

Group type: EXPERIMENTAL
Intervention: Hierarchical approach using DISST family tests
Number of subjects: 71
Study: 22415123

Group type: EXPERIMENTAL
Intervention: Self‐adherent silicone border foam dressing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard preventive care
Number of subjects: 100
Study: 20361906

Group type: EXPERIMENTAL
Intervention: Therapist-controlled ERP performed by experienced behavior therapists
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Therapist-controlled ERP performed by master's students of clinical psychology
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Self-controlled ERP performed by experienced behavior therapists
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Self-controlled ERP performed by master's students of clinical psychology
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: All modes of delivery of ERP
Number of subjects: 118
Study: 19298037

Group type: EXPERIMENTAL
Intervention: Computer-assisted technique
Number of subjects: 44

Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 44
Study: 15804155

Group type: EXPERIMENTAL
Intervention: Coupled temperature measurement system
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CDI 500 arterial temperature sensor
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Increased flow through the CDI sensor to approximately 400 mL/min
Number of subjects: 17
Study: 12424162

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg per day for 14 days)
Number of subjects: 8070
Study: 10836664

Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride vaginal capsule
Number of subjects: 89

Group type: COMPARATOR
Intervention: Benzalkonium chloride pessary
Number of subjects: 89
Study: 9054781

Group type: EXPERIMENTAL
Intervention: Assertive community treatment alone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Assertive community treatment with community workers
Number of subjects: 85

Group type: COMPARATOR
Intervention: Brokered case management
Number of subjects: 85
Study: 8409317

Group type: EXPERIMENTAL
Intervention: GoLYTELY followed by three Dulcolax capsules
Number of subjects: 160

Group type: COMPARATOR
Intervention: GoLYTELY followed by three placebo capsules
Number of subjects: 160
Study: 3096063

Group type: EXPERIMENTAL
Intervention: Intramuscular nicomorphine
Number of subjects: 24

Group type: COMPARATOR
Intervention: High thoracic epidural nicomorphine
Number of subjects: 24
Study: 30686734

Group type: EXPERIMENTAL
Intervention: Active finger movements or passive finger displacements during tactile stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synchronous tactile stimulation at randomized locations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two successive keypresses by different fingers at distinct locations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand movement placed far from the tactile stimulation site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporal synchrony within 600 ms between movement and tactile stimulations
Number of subjects: 0
Study: 29048187

Group type: EXPERIMENTAL
Intervention: Liquid nicotine concentration of 36 mg/ml
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Liquid nicotine concentration of 0, 8, 18, or 36 mg/ml
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: ECIG use
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Puff duration
Number of subjects: 64
Study: 24828225

Group type: EXPERIMENTAL
Intervention: Conventional MRI
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Tumor histology
Number of subjects: 244

Group type: COMPARATOR
Intervention: MRI and histology
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Histology
Number of subjects: 244
Study: 23568034

Group type: COMPARATOR
Intervention: Virtual Chinese abacus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wooden Chinese abacus
Number of subjects: 60
Study: 21712497

Group type: EXPERIMENTAL
Intervention: 400 mg nilotinib as two 200-mg intact capsules
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: nilotinib dispersed in 1 teaspoon of nonfat plain yogurt
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: nilotinib dispersed in 1 teaspoon of applesauce
Number of subjects: 48
Study: 19291387

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 16432825

Group type: EXPERIMENTAL
Intervention: Surgical treatment (flush ligation of sites of reflux, stripping of the long saphenous vein and multiple phlebectomies)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Conservative management (lifestyle advice)
Number of subjects: 246
Study: 15319699

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 45
Study: 10899490

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous combined HRT (ccHRT) containing estradiol (2 mg/d) + estriol (1 mg/d) + norethindrone acetate (1 mg/d)
Number of subjects: 60
Study: 9035017

Group type: EXPERIMENTAL
Intervention: Etodolac 800 mg/day (400 mg bid)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg qid
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg bid
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3

Group type: COMPARATOR
Intervention: Naproxen 1000 mg/day
Number of subjects: 3

Group type: COMPARATOR
Intervention: Nabumetone 1500 mg/day
Number of subjects: 3
Study: 7705193

Group type: EXPERIMENTAL
Intervention: Goshajinkigan (7.5 g/day for 3 months)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Washout period (2 months after discontinuation of Goshajinkigan)
Number of subjects: 13